Through this partnership, Solugen is planning to expand its footprint to include new R&D and production facilities in Southeast Asia to satisfy customer demand in the region across markets.
April 27, 2021. By Manu Tayal
Synthetic biology chemicals manufacturer Solugen has entered into a partnership and investment deal with Singapore’s state fund, Temasek.
It will support further in scaling up and sales growth of the company’s molecular manufacturing platform that harnesses biology to make high-performing, cost effective carbon negative chemicals, ingredients, and materials.
Through this partnership, Solugen is planning to expand its footprint to include new R&D and production facilities in Southeast Asia to satisfy customer demand in the region across markets including clean water, agriculture, and food & beverage.
Speaking on the expansion plans, Dr Gaurab Chakrabarti, co-founder and CEO of Solugen, said “as we rapidly scale our platform to multiple production facilities, we believe Southeast Asia will be an ideal location to deploy our technology given the need for cleaner chemical products to support critical infrastructures such as clean water, agriculture, energy, and food/beverage.”
“We have selected Singapore as our hub in Southeast Asia due to the brilliant talent pool available in the region from key institutions such as A*STAR and NUS, as well as the deep chemicals experience in the region,” said Dr. Sean Hunt, co-founder and CTO of Solugen.
The company has been creating cutting-edge chemistries that are safer to use, and more cost-effective and environmentally-friendly than traditional petrochemicals. It’s innovative carbon-negative chemical solutions, such as BioPeroxide™, BioChelate™ and ScavSol® product lines enable multiple industries to deliver more sustainable products to their customers without compromising performance.
Demand and Willingness to Pay More for High Integrity Credits has Increased in the Market